艾滋病药物绥美凯多少钱

How much do HIV drugs cost? Suimeikai is a new drug approved for marketing in my country in January 2018. It is mainly used to treat adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). The current domestic price of Suimeikai is around 3,000$/month.

Suimeikai is composed of three main ingredients, dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g, one tablet once a day. It has the characteristics of high efficacy, good tolerance, high resistance barrier and few drug interactions.

Judging from a large number of clinical trial data, DTG (dolutegravir) has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR dropped significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%.

From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance. At present, Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

After being launched in my country, it provides a new treatment plan for patients. However, for some patients, the price of the domestic original drug is relatively high, and not all patients can purchase and use it for a long time. Therefore, we might as well choose the Indian version of Suimeikai. The therapeutic effect is basically the same as the original drug, but the price is lower, equivalent to RMB 900 per box. Patients can consult the Medical Travel Overseas Medical Consulting Service Company for detailed information.

Recommended related hot articles: /newsDetail/80779.html